Syngene International Ltd.
https://syngeneintl.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Syngene International Ltd.
Syngene Chief: Large Cap Biopharma Taking China 'Rotation' More Seriously
A material shift in China derisking discussions by big biopharma against the backdrop of the proposed US BIOSECURE Bill is seen presenting opportunities for Syngene, though the tight US biotech funding environment dampened demand for the Indian CRDMO’s R&D services in Q4.
Adopt Unilever Model, Tech To Prevent ‘India Plus One’ Situation – CRDMO CXOs
CRDMO CXOs sketch a promising landscape for the Indian industry, highlighting technology, scale and talent, particularly millennials and Gen Z, as key factors in a SWOT analysis - while cautioning that a global ‘China plus one’ strategy could turn to a ‘India plus one’ too.
BMS’ Boerner Bets On AI-Driven R&D In India, Points To Potential For MS, Lupus Drugs
Bristol Myers Squibb CEO Christopher Boerner is looking to India to house the the company’s largest R&D site outside of the US, channeling the country's IT expertise to expand its AI-driven small-molecule research. He also wants to bring its drugs to treat multiple sclerosis and Lupus to India.
No 'Constraining Situation' On Generic Vascepa API, Says Strides MD
Strides intends to keep US momentum going with Amneal-partnered generic Vascepa, where Hikma and Dr. Reddy’s have filed antitrust suits against Amarin over API supply. Meanwhile, the founder re-iterated ambitious goals set for Stelis and its CDMO business.
Company Information
- Industry
- Biotechnology
- Contract Research Organization-CRO
- Diversified
- Pharmaceuticals
- Services
- Contract Manufacturing Organization
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice